Download PDF
Planta Med 1997; 63(5): 433-435
DOI: 10.1055/s-2006-957728
Papers
Pharmacology
© Georg Thieme Verlag Stuttgart · New York

Experimental Treatment of Cutaneous Leishmaniasis with Argentilactone Isolated from Annona haematantha

Anne Isabelle Waechter1 , Maria Elena Ferreira2 , Alain Fournet3 , Antonieta Rojas de Arias2 , Hector Nakayama2 , Susana Torres2 , Reynald Hocquemiller1 , André Cavé1
  • 1Laboratoire de Pharmacognosie, BIOCIS URA 1843 CNRS, Faculté de Pharmacie, Rue J.-B. Clément, F-92296 Châtenay-Malabry Cedex, France
  • 2Instituto de Investigaciones en Ciencias de la Salud, Department of Tropical Medicine, Casilla de Correo 2511, Asunción, Paraguay
  • 3Institut Français de Recherche Scientifique pour le Développement en Coopération (ORSTOM), CC 97, Asuncion, Paraguay
Further Information

Publication History

1996

1997

Publication Date:
04 January 2007 (online)

  PDF Download  Permissions and Reprints

Abstract

From the hexanic extract of roots of Annona haematantha an α,β-unsaturated δ-lactone was isolated and identified as argentilactone. This compound exhibited in vitro activity against various strains of Leishmania ssp. at 10 µg/ml. BALB/c mice infected with Leishmania amazonensis were treated four weeks after infection with argentilactone by oral or subcutaneous routes for 14 days at 25 mg/kg daily. The reference drug, N-methylglucamine antimonate, was administered by subcutaneous injections at l00 mg/kg for 14 days. In these conditions, argentilactone showed the same efficacy as the reference drug, reducing by 96% the parasite loads in the lesion and by 50% the parasite burden in spleen.

key words

Annona haematantha - Annonaceae - argentilactone - BALB/c mice - Leishmania amazonensis

      >